In a session moderated by Nathalie Pinkerton of New York University, leading researchers spoke about how working with a foundation, a company, and a venture capital firm enabled them to accelerate cancer research. This panel featured Princeton faculty members Yibin Kang, Josh Rabinowitz and Mona Singh, as well as Eileen White of the Rutgers Cancer Institute of New Jersey. Kang, Rabinowitz and White are the founding members of the new Ludwig Institute for Cancer Research Princeton Branch.
This session was part of Engage 2021, Princeton University's 2nd annual innovation and entrepreneurship conference. The conference was live streamed December 1-2, 2021. Engage brings together researchers, innovators, entrepreneurs, industry, government and stakeholders from throughout the innovation ecosystem to catalyze the transformation of research into innovations that impact the world. Engage 2021 was hosted by Princeton Innovation and organized by the Office of Corporate Engagement and Foundation Relations. https://bit.ly/PrincetonEngage2021PlaylistSummary
Princeton Innovation is the University’s campus-wide initiative to extend the benefits of Princeton discoveries into the world to create solutions for humanity. Princeton Innovation emerges from the University’s commitment to service, research and education.
Session Date and Time: Wednesday, December 1, 2021, 11:00 AM-11:45 AM ET
Speakers: Mark Esposito - Chief Executive Officer and Founder, KayoThera
Yibin Kang - Warner-Lambert/Parke-Davis Professor of Molecular Biology, Princeton University; Principal Investigator and Founding Member, Ludwig Institute for Cancer Research, Princeton Branch
Nathalie Pinkerton - Assistant Professor of Chemical and Biomolecular Engineering, New York University
Joshua Rabinowitz - Professor of Chemistry and the Lewis-Sigler Institute for Integrative Genomics, Princeton University; Director and Founding Member, Ludwig Institute for Cancer Research, Princeton Branch
Mona Singh - Professor of Chemistry and the Lewis-Sigler Institute for Integrative Genomics, Princeton University
Eileen White - Deputy Director, Chief Scientific Officer and Associate Director of Basic Research, Rutgers Cancer Institute of New Jersey; Associate Director, Founding Member and Principal Investigator, Ludwig Institute for Cancer Research, Princeton Branch
This session was organized by the Office of Corporate Engagement and Foundation Relations.
